Latest news with #WallSt
News.com.au
2 hours ago
- Business
- News.com.au
Major tech companies post huge earnings, sparking Wall St frenzy
Tech giants Meta and Microsoft have posted huge earnings, shocking Wall St and sending their stock prices soaring on after hours trading. Meta reported its revenue jumped 22 per cent year-on-year to US$47.5 billion ($76.73 billion) as the social media giant continues investing heavily in artificial intelligence (AI). The Facebook and Instagram owner's share price soared as much as 12 per cent in after-hours trading, with investors buoyed by the company's growing advertising business and a rise in users across its family of platforms. 'We've had a strong quarter both in terms of our business and community,' chief executive Mark Zuckerberg said. 'I'm excited to build personal superintelligence for everyone in the world.' Meanwhile competitor Microsoft revealed its profit soared above expectations in the recently ended quarter, driven by its cloud computing and AI units. Microsoft reported revenue of US$76.4 billion ($118.56 billion), some $29.9 billion of which was brought in by its Intelligent Cloud business, with US$27.2 billion ($45.3 billion) in profit. 'Cloud and AI is the driving force of business transformation across every industry and sector,' Microsoft chief executive Satya Nadella said in an earnings release. 'We're innovating across the tech stack to help customers adapt and grow in this new era.' Microsoft's share price rose about eight per cent after trading closed for the day on Wednesday, US time. The news came as Wall St was mostly down due to the Federal Reserve's decision to keep interest rates on hold, despite pressure from Donald Trump. Meanwhile, the ASX200 here in Australia is down 0.25 per cent. AI boom, job cuts In July, Microsoft slashed almost four per cent of its global workforce as it sought to cut layers of middle management and leverage new technologies. 'We continue to implement organisational changes necessary to best position the company and teams for success in a dynamic marketplace,' a Microsoft spokesperson said in an email. The cuts followed another round in May that saw about 6,000 positions culled from its global workforce. Meta posted a net profit of US$18.3 billion ($28.4 billion), compared with US$13.5 billion ($20.9 billion) in the same period last year. Meta's Family of Apps segment, which includes Facebook, Instagram, WhatsApp and Messenger, saw daily active users reach 3.48 billion in June, up six per cent from a year earlier. The company significantly increased its capital expenditures to US$17 billion ($26 billion) in the quarter, primarily for AI infrastructure investments. Mr Zuckerberg has embarked on a major AI spending spree, poaching top researchers with expensive pay packages from rivals like OpenAI and Apple as he builds a team to pursue what he calls AI superintelligence. 'To win the superintelligence race requires the best of the best talent and Meta's been on a roll when it comes to recruiting top AI talent. Money talks and Meta has plenty of it,' Forrester research director Mike Proulx said. The big question is whether Wall St will continue backing the expensive strategy. Tech behemoths are locked in an AI arms race as they invest heavily in the field, aiming to ensure the technology benefits society and generates profits in the not-so-distant future.
Yahoo
6 days ago
- Business
- Yahoo
3 European Growth Companies With Insider Ownership Seeing Up To 114% Earnings Growth
As European markets navigate a landscape of mixed stock index performances and ongoing trade discussions, investors are keenly observing growth opportunities within the region. In this context, companies with high insider ownership often draw attention due to their potential for alignment between management and shareholder interests, making them intriguing candidates in today's market environment. Top 10 Growth Companies With High Insider Ownership In Europe Name Insider Ownership Earnings Growth Xbrane Biopharma (OM:XBRANE) 21.8% 56.8% Pharma Mar (BME:PHM) 11.8% 43.3% MedinCell (ENXTPA:MEDCL) 13.9% 130.8% Marinomed Biotech (WBAG:MARI) 29.7% 20.2% KebNi (OM:KEBNI B) 38.3% 94.5% Elliptic Laboratories (OB:ELABS) 24.4% 79% CTT Systems (OM:CTT) 17.5% 37.9% Circus (XTRA:CA1) 24.7% 94.8% Bonesupport Holding (OM:BONEX) 10.4% 62.3% Bergen Carbon Solutions (OB:BCS) 12% 63.2% Click here to see the full list of 214 stocks from our Fast Growing European Companies With High Insider Ownership screener. Here's a peek at a few of the choices from the screener. Paratus Energy Services Simply Wall St Growth Rating: ★★★★☆☆ Overview: Paratus Energy Services Ltd. operates through its subsidiaries to provide drilling services with a fleet of jack-up rigs under contracts in Mexico, and it has a market capitalization of NOK6.35 billion. Operations: The company's revenue segments include $205 million from Fontis and $197.80 million from Seagems. Insider Ownership: 30.3% Earnings Growth Forecast: 36.5% p.a. Paratus Energy Services has significant growth potential, with earnings forecasted to grow at 36.5% annually, outpacing the Norwegian market's 10.8%. Despite a decline in Q1 sales and net income compared to last year, the company maintains a high return on equity projection of 96.1% within three years. However, revenue growth is expected to lag behind the market at just 0.9%. The stock trades significantly below its estimated fair value but faces challenges with interest coverage from earnings. Dive into the specifics of Paratus Energy Services here with our thorough growth forecast report. According our valuation report, there's an indication that Paratus Energy Services' share price might be on the cheaper side. Devyser Diagnostics Simply Wall St Growth Rating: ★★★★★☆ Overview: Devyser Diagnostics AB (publ) develops, manufactures, and sells diagnostic kits and solutions for DNA testing related to hereditary diseases, oncology, and post-transplantation monitoring across multiple regions including Europe, the Middle East, Africa, the Americas, and Asia with a market cap of approximately SEK2.52 billion. Operations: The company's revenue is primarily derived from the sale of diagnostic kits and equipment, amounting to SEK235.10 million. Insider Ownership: 35.4% Earnings Growth Forecast: 115.0% p.a. Devyser Diagnostics shows promising growth potential, with revenue projected to grow at 27.7% annually, significantly outpacing the Swedish market's 5.2%. The company recently reported a turnaround in Q2 earnings, achieving SEK 1.3 million net income compared to a loss last year. Devyser's innovative product launches in genomic blood typing and HLA loss detection bolster its research capabilities and market position. Despite low return on equity forecasts, profitability is expected within three years. Unlock comprehensive insights into our analysis of Devyser Diagnostics stock in this growth report. In light of our recent valuation report, it seems possible that Devyser Diagnostics is trading beyond its estimated value. Surgical Science Sweden Simply Wall St Growth Rating: ★★★★☆☆ Overview: Surgical Science Sweden AB (publ) specializes in developing and marketing virtual reality simulators for evidence-based medical training globally, with a market cap of SEK8.08 billion. Operations: The company generates revenue through two main segments: Industry/OEM, contributing SEK460.22 million, and Educational Products, accounting for SEK486.31 million. Insider Ownership: 14.8% Earnings Growth Forecast: 32.5% p.a. Surgical Science Sweden demonstrates strong growth potential with earnings projected to grow 32.54% annually, outpacing the Swedish market's 16.9%. Recent Q1 results show sales of SEK 250.69 million and net income of SEK 33.24 million, reflecting positive year-over-year growth. Despite a lower profit margin than last year, insider activity remains positive with more shares bought than sold recently. The company trades at a significant discount to its estimated fair value, indicating potential investment appeal amidst board leadership changes. Delve into the full analysis future growth report here for a deeper understanding of Surgical Science Sweden. Our expertly prepared valuation report Surgical Science Sweden implies its share price may be too high. Turning Ideas Into Actions Click through to start exploring the rest of the 211 Fast Growing European Companies With High Insider Ownership now. Ready To Venture Into Other Investment Styles? Outshine the giants: these 20 early-stage AI stocks could fund your retirement. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years. Companies discussed in this article include OB:PLSV OM:DVYSR and OM:SUS. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
6 days ago
- Business
- Yahoo
High Growth European Tech Stocks with Promising Potential
As the pan-European STOXX Europe 600 Index remains relatively flat amid ongoing U.S. and European trade discussions, and with mixed performances across major stock indexes in the region, investors are keenly watching for opportunities in sectors poised for growth. In this context, identifying high-growth tech stocks that can capitalize on economic expansions such as the recent uptick in eurozone industrial output becomes crucial for those looking to navigate Europe's dynamic market landscape. Top 10 High Growth Tech Companies In Europe Name Revenue Growth Earnings Growth Growth Rating Intellego Technologies 28.42% 47.04% ★★★★★★ Archos 24.72% 39.34% ★★★★★★ Pharma Mar 26.67% 43.29% ★★★★★★ innoscripta 24.76% 26.32% ★★★★★★ KebNi 20.56% 94.46% ★★★★★★ Bonesupport Holding 23.98% 62.26% ★★★★★★ Skolon 31.51% 99.52% ★★★★★★ Xbrane Biopharma 24.95% 56.77% ★★★★★★ Rubean 45.56% 108.82% ★★★★★★ Elliptic Laboratories 36.33% 78.99% ★★★★★★ Click here to see the full list of 232 stocks from our European High Growth Tech and AI Stocks screener. Here's a peek at a few of the choices from the screener. Dynavox Group Simply Wall St Growth Rating: ★★★★★☆ Overview: Dynavox Group AB (publ) develops and sells assistive technology products for individuals with impaired communication skills, with a market cap of SEK13.47 billion. Operations: Dynavox Group AB focuses on assistive technology products, generating revenue primarily from computer hardware sales, amounting to SEK2.25 billion. Despite recent volatility in its share price, Dynavox Group demonstrates robust potential within Europe's tech sector, marked by a notable 15.4% annual revenue growth outpacing the Swedish market's 5.2%. The firm recently reported a significant uptick in sales to SEK 1.18 billion over six months, up from SEK 904 million the previous year, underscoring strong market demand. Moreover, with earnings forecasted to surge by an impressive 48.7% annually, Dynavox is strategically leveraging its R&D investments to innovate and stay competitive in high-tech arenas. This focus on development is crucial as it aligns with industry shifts towards more integrated tech solutions. Additionally, the company repurchased shares under a new program starting May 9, emphasizing confidence in its future trajectory and commitment to shareholder value amidst strategic expansions. Navigate through the intricacies of Dynavox Group with our comprehensive health report here. Review our historical performance report to gain insights into Dynavox Group's's past performance. Hanza Simply Wall St Growth Rating: ★★★★☆☆ Overview: Hanza AB (publ) offers comprehensive manufacturing solutions and has a market capitalization of approximately SEK5.27 billion. Operations: The company generates revenue primarily from its Main Markets segment, contributing SEK3.11 billion, and Other Markets segment with SEK2.16 billion. Business Development and Services add a smaller portion at SEK32 million. Amidst a dynamic European tech landscape, Hanza stands out with its impressive financial performance. Over the past year, the company's earnings surged by 19.9%, significantly outpacing the electronic industry's growth of 6.6%. This trend is expected to continue, with projected annual earnings growth of 34.7%, well above Sweden's market average of 16.9%. Moreover, Hanza's commitment to innovation is evident in its R&D investments, which are crucial as it adapts to evolving technological demands and maintains competitive edge in integrated tech solutions. Recent financial reports underscore this trajectory: for Q2 2025 alone, sales hit SEK 1.52 billion—a substantial increase from SEK 1.22 billion in the previous year—while net income soared to SEK 52 million from just SEK 6 million, reflecting robust operational efficiency and market responsiveness. Dive into the specifics of Hanza here with our thorough health report. Learn about Hanza's historical performance. Vitrolife Simply Wall St Growth Rating: ★★★★☆☆ Overview: Vitrolife AB (publ) is a company that offers assisted reproduction products across Europe, the Middle East, Africa, Asia-Pacific, and the Americas with a market capitalization of approximately SEK19.95 billion. Operations: Vitrolife generates revenue primarily from three segments: Genetics (SEK1.46 billion), Consumables (SEK1.39 billion), and Technologies (SEK691 million). Vitrolife, a player in the European biotech sector, has shown resilience with a revenue growth forecast of 6.7% per year, outpacing the Swedish market's 5.2%. This growth is complemented by an earnings projection of 22.3% annually, significantly above the market average. Despite recent dips in quarterly sales and net income—SEK 871 million and SEK 100 million respectively compared to higher figures last year—the company's strategic financial maneuvers like securing a EUR 300 million loan indicate robust credit confidence and potential for sustained expansion. Get an in-depth perspective on Vitrolife's performance by reading our health report here. Understand Vitrolife's track record by examining our Past report. Key Takeaways Embark on your investment journey to our 232 European High Growth Tech and AI Stocks selection here. Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up. Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free. Contemplating Other Strategies? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include OM:DYVOX OM:HANZA and OM:VITR. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
6 days ago
- Business
- Yahoo
European Growth Companies With High Insider Ownership To Watch
As the European markets navigate a landscape of mixed stock index performances and ongoing trade discussions with the U.S., investors are keenly observing economic indicators such as inflation and industrial output. In this environment, growth companies with substantial insider ownership can be particularly appealing, as they often signal strong internal confidence and alignment of interests between management and shareholders. Top 10 Growth Companies With High Insider Ownership In Europe Name Insider Ownership Earnings Growth Xbrane Biopharma (OM:XBRANE) 21.8% 56.8% Pharma Mar (BME:PHM) 11.8% 43.3% MedinCell (ENXTPA:MEDCL) 13.9% 130.8% Marinomed Biotech (WBAG:MARI) 29.7% 20.2% KebNi (OM:KEBNI B) 38.3% 94.5% Elliptic Laboratories (OB:ELABS) 24.4% 79% CTT Systems (OM:CTT) 17.5% 37.9% Circus (XTRA:CA1) 24.7% 94.8% Bonesupport Holding (OM:BONEX) 10.4% 62.3% Bergen Carbon Solutions (OB:BCS) 12% 63.2% Click here to see the full list of 214 stocks from our Fast Growing European Companies With High Insider Ownership screener. Here's a peek at a few of the choices from the screener. PostNL Simply Wall St Growth Rating: ★★★★☆☆ Overview: PostNL N.V. offers postal and logistics services to businesses and consumers in the Netherlands, Europe, and internationally, with a market cap of €536.66 million. Operations: The company's revenue is primarily derived from its Parcels segment, generating €2.39 billion, and the Mail in The Netherlands segment, contributing €1.33 billion. Insider Ownership: 35.1% Earnings Growth Forecast: 32.9% p.a. PostNL is experiencing significant earnings growth, forecasted at 32.88% annually, outpacing the Dutch market's 9.1%. Despite a recent net loss of €17 million for Q1 2025, this marks an improvement from the previous year's €20 million loss. However, revenue growth remains modest at 1.9% per year and below the market average of 7.3%. The company faces challenges with high debt levels and volatile share prices but trades significantly below its estimated fair value. Delve into the full analysis future growth report here for a deeper understanding of PostNL. Upon reviewing our latest valuation report, PostNL's share price might be too optimistic. Medicover Simply Wall St Growth Rating: ★★★★★☆ Overview: Medicover AB (publ) offers healthcare and diagnostic services in Poland, Sweden, and internationally, with a market cap of SEK43.03 billion. Operations: The company's revenue segments include healthcare services at €1.17 billion and diagnostic services at €0.80 billion. Insider Ownership: 11.2% Earnings Growth Forecast: 23.5% p.a. Medicover shows strong growth potential, with earnings forecasted to grow significantly at 23.5% annually, surpassing the Swedish market's average. Recent earnings reports highlight a substantial increase in net income and revenue for the first half of 2025. Despite no substantial insider buying recently, insider transactions have been more purchases than sales. Medicover's innovative MRD assay development marks a promising advancement in personalized cancer treatment, potentially enhancing its market position and supporting future growth prospects. Take a closer look at Medicover's potential here in our earnings growth report. Our expertly prepared valuation report Medicover implies its share price may be too high. Yubico Simply Wall St Growth Rating: ★★★★★☆ Overview: Yubico AB offers authentication solutions for computers, networks, and online services with a market cap of SEK12 billion. Operations: The company's revenue primarily comes from its Security Software & Services segment, totaling SEK2.45 billion. Insider Ownership: 36.5% Earnings Growth Forecast: 23.9% p.a. Yubico demonstrates strong growth potential with earnings expected to grow significantly at 23.9% annually, outpacing the Swedish market. Recent expansions, including YubiKey as a Service in the EU and increased delivery coverage, enhance its market reach and operational efficiency against phishing threats. Despite a decline in net income for Q1 2025, insider buying has been substantial recently, indicating confidence in future prospects. The company trades at good value compared to peers within the industry. Click to explore a detailed breakdown of our findings in Yubico's earnings growth report. Upon reviewing our latest valuation report, Yubico's share price might be too pessimistic. Where To Now? Click here to access our complete index of 214 Fast Growing European Companies With High Insider Ownership. Want To Explore Some Alternatives? This technology could replace computers: discover the 27 stocks are working to make quantum computing a reality. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years. Companies discussed in this article include ENXTAM:PNL OM:MCOV B and OM:YUBICO. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
News.com.au
10-07-2025
- Business
- News.com.au
Market wrap: ASX200 lifts on Wall St rally and iron ore surge
A Wall St rally and lift in iron ore prices propelled the Australian sharemarket higher on Thursday, as investors shrugged on tariff uncertainty and piled back into risk assets. The benchmark ASX200 jumped 50.6 points, or 0.59 per cent, to close at 8589.2, while the broader All Ordinaries index lifted 48.8 points or 0.56 per cent, to finish at 8826.7. The heavyweight materials sector led the charge, gaining 1.24 per cent. Singapore iron ore futures advanced 3 per cent to $US98.95 a tonne in afternoon trade on the back of Wednesday's better-than-expected consumer inflation data out of China. 'This snapped a run of four months of consumer deflation and buoyed hopes that stimulus measures and easing trade risks with the US will boost China-facing stocks by the end of the year,' IG market analyst Tony Sycamore said. BHP gained 1.19 per cent to $38.30 a share, Rio Tinto climbed nearly 1 per cent to $108.62, Fortescue rose 1.91 per cent to $16.51 and Mineral Resources added 3.66 per cent to $25.51. Gold miners advanced as the precious metal hit US$3330 an ounce. Evolution Mining jumped 3.57 per cent to $7.55 while Newmont rose 3.24 per cent to $90.29. Financials also lifted, with Commonwealth Bank advancing 0.82 per cent to $180.37, Westpac edging up 0.5 per cent to $33.87, NAB climbing 1.12 per cent to $39.74 and ANZ gaining 0.77 per cent to $30.29. Seven of 11 industry sectors ended in the green, though the healthcare sector continued to sell off, losing another 0.54 per cent following US President Donald Trump's threat this week to impose a 200 per cent tariff on pharmaceutical imports. CSL retreated 0.53 per cent to $242.41 while Ramsay Healthcare tumbled 3.09 per cent to $37.92. The market briefly broke through the 8600 barrier in intraday trading, reaching a high mark of 8610 points just before 1pm. The bourse's gains followed a strong lead from Wall St overnight on Wednesday as confidence grew about a possible rate cut from the US Federal Reserve later in the year. The Dow Jones added 217 points, or 0.49 per cent, to close at 44,458, while the S&P500 rose 0.61 per cent to 6263.26 and the tech-heavy Nasdaq index surged 0.94 per cent to 20,611. 'The central bank kept interest rates steady at 4.25 per cent to 4.5 per cent, signalling confidence in the economy, even as inflation, while easing, remains stubbornly above its 2 per cent target,' Moomoo market strategist Jessica Amir said. 'The labour market continues to impress, with low unemployment and steady job gains providing a sturdy backbone for growth. 'Yet central bank officials are treading carefully. Global uncertainties, shifting trade dynamics and geopolitical tensions remain firmly on its radar. 'While some officials see room for possible rate cuts later this year if inflation cools further, the consensus is clear: no rushing into decisions.' In corporate news, medical devices company Imricor Medical Systems slumped 15.1 per cent to $1.32 after updating investors on its regulatory approvals progress in the US. The top gainer on the ASX200 was Lifestyle Communities, which surged 9.2 per cent to $4.83. The biggest loser was Domino's Pizza, slumping 4 per cent to $18.03. The Aussie dollar gained 0.28 per cent to buy US65.5c at the closing bell.
